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Abstract: Objective: Tissue engineering of viable, autologous cardiovascular replacements with the po-
tential to grow, repair and remodel represents an attractive approach to overcome the shortcomings of
available replacements for the repair of congenital cardiac defects. Currently, vascular myofibroblast cells
represent an established cell source for cardiovascular tissue engineering. Cell isolation requires the inva-
sive harvesting of venous or arterial vessel segments prior to scaffold seeding, a technique which may not
be preferable, especially in pediatric patients. This study evaluates cells isolated from human umbilical
cord artery, umbilical cord vein and whole cord as alternative autologous cell sources for cardiovascular
tissue engineering. Methods: Cells were isolated from human umbilical cord artery (UCA), umbilical cord
vein (UCV), whole umbilical cord (UCC) and saphenous vein segments (VC), and were expanded in cul-
ture. All three expanded cell groups were seeded on bioabsorbable copolymer strips and grown in vitro for
28 days. Isolated cells were characterized by flow cytometry, histology, immunohistochemistry, prolifera-
tion assays and compared to VC. Morphological analysis of the seeded polymer strips included histology,
immunohistochemistry, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transmission electron
microscopy (TEM), scanning electron microscopy (SEM) and uniaxial stress testing. Results: UCA, UCV
and UCC demonstrated excellent cell growth properties comparable to VC. Following isolation, all three
cell groups showed myofibroblast-like morphology and characteristics by staining positive for ￿-smooth
muscle actin (ASMA) and vimentin. Histology and immunohistochemistry of seeded polymers showed
good tissue and extracellular matrix formation containing collagen I, III and elastin. TEM showed vi-
able myofibroblasts and the deposition of collagen fibrils and progessive growing tissue formation, with
a confluent surface, was observed in SEM. No difference was found among the mechanical properties
of UCA, UCV, UCC and VC tissue engineered constructs. Conclusions: Tissue engineering of cardio-
vascular constructs by using UCA, UCV and UCC is feasible in an in vitro environment. Cell growth,
morphology, characteristics and tissue formation were comparable between UCA, UCV, UCC and VC.
UCC represent an attractive, readily available autologous cell source for cardiovascular tissue engineering
offering the additional benefits of utilizing juvenile cells and avoiding the invasive harvesting of intact
vascular structures
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Abstract
Objective: Tissue engineering of viable, autologous cardiovascular replacements with the potential to grow, repair and remodel represents
an attractive approach to overcome the shortcomings of available replacements for the repair of congenital cardiac defects. Currently,
vascular myofibroblast cells represent an established cell source for cardiovascular tissue engineering. Cell isolation requires the invasive
harvesting of venous or arterial vessel segments prior to scaffold seeding, a technique which may not be preferable, especially in pediatric
patients. This study evaluates cells isolated from human umbilical cord artery, umbilical cord vein and whole cord as alternative autologous
cell sources for cardiovascular tissue engineering. Methods: Cells were isolated from human umbilical cord artery (UCA), umbilical cord
vein (UCV), whole umbilical cord (UCC) and saphenous vein segments (VC), and were expanded in culture. All three expanded cell groups
were seeded on bioabsorbable copolymer strips and grown in vitro for 28 days. Isolated cells were characterized by flow cytometry,
histology, immunohistochemistry, proliferation assays and compared to VC. Morphological analysis of the seeded polymer strips included
histology, immunohistochemistry, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transmission electron microscopy (TEM),
scanning electron microscopy (SEM) and uniaxial stress testing. Results: UCA, UCV and UCC demonstrated excellent cell growth
properties comparable to VC. Following isolation, all three cell groups showed myofibroblast-like morphology and characteristics by
staining positive for a-smooth muscle actin (ASMA) and vimentin. Histology and immunohistochemistry of seeded polymers showed good
tissue and extracellular matrix formation containing collagen I, III and elastin. TEM showed viable myofibroblasts and the deposition of
collagen fibrils and progessive growing tissue formation, with a confluent surface, was observed in SEM. No difference was found among the
mechanical properties of UCA, UCV, UCC and VC tissue engineered constructs. Conclusions: Tissue engineering of cardiovascular
constructs by using UCA, UCV and UCC is feasible in an in vitro environment. Cell growth, morphology, characteristics and tissue
formation were comparable between UCA, UCV, UCC and VC. UCC represent an attractive, readily available autologous cell source for
cardiovascular tissue engineering offering the additional benefits of utilizing juvenile cells and avoiding the invasive harvesting of intact
vascular structures.
q 2004 Elsevier B.V. All rights reserved.
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1. Introduction
The repair of congenital cardiac defects frequently
requires the application of synthetic or bioprosthetic
replacements, such as patch material or vascular conduits.
All clinically available replacements demonstrate signifi-
cant disadvantages which limit their long-term benefits.
Shortcomings include the lack of a growth potential, an
obstructive tissue ingrowth, and calcification of the
prosthetic replacements, which necessitates multiple oper-
ations in pediatric patients [1–3]. Currently, cryopreserved
homograft tissue appears to offer the most attractive solution
by containing, theoretically, some viability with a potential
growth ability [4–6]. Following implantation in children,
these grafts are subject to enhanced calcification and donor
scarcity remains a significant problem for pediatric patients
[7–9].
The creation of tissue engineered viable replacement
structures with the potential to grow, to repair and to
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remodel may offer a promising alternative for pediatric
patients. Several groups demonstrated the feasibility of
tissue engineering cardiovascular structures such as pul-
monary artery conduits, patch material, trileaflet heart
valves and vessel grafts by using three-dimensional
scaffolds of synthetic polymer, collagen or xenogenic origin
[10–13]. Recent results reported in the first clinical
application of a tissue engineered pulmonary artery conduit,
following implantation in a pediatric patient, are encoura-
ging [14]. So far it remains unclear whether these tissue
engineered constructs will function under physiologic
conditions in the long-term.
Presently, autologous vascular-derived myofibroblasts
represent an established cell source for the tissue
engineering of functioning cardiovascular structures.
Prior to scaffold seeding, arterial or venous-derived
myofibroblasts are isolated from segments of aorta,
carotis or saphenous vein segments. An approach,
requiring the invasive harvesting of intact vascular
structures.
The present study evaluates cells isolated from umbilical
cord artery, umbilical cord vein and whole umbilical cord as
alternative autologous cell sources for cardiovascular tissue
engineering. The application of umbilical cord cells would
provide autologous cells without the harvesting of intact
vascular structures, which appears to be an advantage,
especially in pediatric patients.
2. Material and methods
2.1. Cell isolation and cultivation
Human umbilical cords (20–30 cm length) ðn ¼ 4Þ and
saphenous vein segments (2–3 cm length) ðn ¼ 4Þ were
freshly harvested, washed with Dulbecco’s phosphate
buffered saline (DPBS) (Gibco), and placed in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco) supplemented
with 10% fetal bovine serum (HyClone) and Gentamycin
(25 mg/ml) (Gibco). Umbilical cord artery and venous
segments were isolated from whole cord. The tissue
sections were processed for subsequent tissue cultivation
between 30 and 60 min after harvest and following,
pieces of umbilical cord artery, umbilical cord vein,
whole umbilical cord, and saphenous vein were minced
into 1 mm pieces and distributed in 100 £ 15 mm Petri
dishes (Gibco BRL, Rockville, MD). Tissue sections were
cultured with DMEM (Gibco) supplemented with 10%
fetal bovine serum (HyClone) and Gentamycin (25 mg/ml)
(Gibco). Medium was replaced at 24 and 72 h and every
six days following. Daily progress was monitored by
phase-contrast microscopy. The cells were serially
passaged and expanded in a humidified incubator at
37 8C with 5% CO2. Sufficient cell numbers for seeding
of polymer scaffolds were obtained after a period of
18–21 days.
2.2. Polymer scaffolds
Non-woven polyglycolic-acid mesh (PGA) (Albany Int.)
was coated with a thin layer of poly-4-hydroxybutyrate
(P4HB, MW: 1 £ 106, PHA 4400, Tepha Inc., Cambridge,
MA) by dipping into a tetrahydrofuran solution (1% wt/vol
P4HB). Following solvent evaporation, a continuous coating
and physical bonding of adjacent fibers was achieved. PH4B
is a biologically derived biopolymer which shows a complete
biodegradation after 6-8 weeks. Polymer scaffold strips
(5 £ 2 cm; n ¼ 14s) were cut from the PGA/P4HB compo-
site material and cold gas sterilized with ethylene oxide.
2.3. Cell seeding and in vitro culture of polymer constructs
Bioabsorbable polymer scaffolds were seeded with an
approximate density of 4.5-5.5 £ 106 UCC or VC per cm2
and cultured in DMEM supplemented with 10% fetal bovine
serum and Gentamycin (25 mg/ml) in a humidified incu-
bator (37 8C, 5%CO2) for 28 days.
2.4. Flow cytometry
Single cell suspensions of UCA, UCV, UCC and VC
were prepared for flow cytometry. 0.5 £ 106 cells in 100 ml
HANKS solution plus 1%BSA were incubated with
saturating concentrations of monoclonal antibodies CD
31-FITC (Clone LCI4 þ 6 þ 7, kindly provided by
P. Kilshaw), ASMA (Clone 1A4, Sigma, St Louis, MI),
and vimentin (Clone V9, NeoMarkers, Fremont, CA). For
intracellular staining (ASMA, vimentin) cells were permea-
bilized with ethanol for 60 min at room temperature and
incubated with monoclonal antibodies for 30 min. Follow-
ing washing, staining with a secondary FITC-conjugated
IgG goat-anti-mouse antibody (Chemicon, Temecula, CA)
was performed for 30 min. Forward and side scatters were
set to exclude debris and 10,000 gated events were counted
per sample. Corresponding irrelevant isotype-matched and
positive controls were performed for each antibody. Cells
were analyzed with the flow cytometer FACS-Calibur
(Becton Dickinson Immunocytometry Systems, San Jose,
CA). Data analysis was performed with the CELL QUEST
software program (Becton Dickinson Immunocytometry
Systems, San Jose, CA). Expression levels were calculated
as mean fluorescence intensity ratio (MFIR) defined as
mean fluorescence intensity of the studied antibodies
divided by mean fluorescence intensity of corresponding
isotype controls.
2.4.1. Histology and immunohistochemistry
of umbilical cords
Sections of umbilical cords ðn ¼ 4Þ were fixed in 4%
phosphate-buffered formalin and embedded in paraffin.
Paraffin sections were cut at 5-mm thickness and studied by
hematoxylin–eosin and Trichrome-masson stain. Immu-
nohistochemistry was performed by incubation with
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monoclonal mouse antibodies for ASMA (Sigma, St Louis,
MI), vimentin (NeoMarkers, Fremont, CA) and a secondary
FITC-labeled goat-anti-mouse IgG antibody (Sima, St Louis,
MI). Prior to intracellular staining, tissue sections were
treated with 0.1% Triton (Sigma, St Louis, MI) for 10 min.
2.4.2. Histology and Immunohistochemistry
of UCA, UCV, and UCC cultures
Samples of UCA, UCV and UCC were cultivated onto
glass coverslips in DMEM. After 2–3 days cells were
washed with DPBS and fixed in methanol for 10 min. Cells
were examined histologically by hematoxylin–eosin and
Trichrome-masson stain. Immunohistochemistry was per-
formed by incubation with monoclonal mouse antibodies
for ASMA (Sigma, St Louis, MI), vimentin (NeoMarkers,
Fremont, CA), elastin (Sigma, St Louis, MI), and collagen I,
III (Oncogen, Boston, MA). Incubation with a secondary
FITC-labeled goat-anti-mouse IgG antibody (Sima, St
Louis, MI) and a biotin-labeled goat-anti-mouse IgG
antibody (Sima, St Louis, MI) to elastin, and collagen I
and III was performed. The biotin-labeled antibody signal
was developed with the avidin–peroxidase system (ABC
kit, Vector Lab, Burlingame, CA). Prior to intracellular
staining for ASMA and vimentin permeabilization of the
cells was performed by incubation with 0.1% Triton (Sigma,
St Louis, MI) for 10 min.
2.4.3. MTT assay
Following isolation from umbilical cord and saphenous
vein segments, UCA ðn ¼ 4Þ; UCV ðn ¼ 4Þ; UCC ðn ¼ 4Þ
and VC ðn ¼ 4Þ were seeded in 24-well plates with a density
of 5 £ 104 cells/ml per well and cultured with DMEM. MTT
assays were performed on days 1, 3, 6 and 8. Two hundred
and fifty microliters medium and 20 ml MTT solution
(Sigma, St Louis, MI) were added to each sample and
incubated for 1 h at 37 8C followed by isopropanol for 5 min
at RT. The optical density of the supernatants were
measured at 570 nm and growth curves developed.
2.5. Analysis of UCA, UCV, and UCC-seeded polymer
constructs
2.5.1. Histology and Immunohistochemistry
Sections of UCA, UCV, and UCC-seeded polymer
scaffolds were fixed in 4% phosphate-buffered formalin and
embedded in paraffin. Paraffin sections were cut at 5 mm
thickness and studied by hematoxylin–eosin and Trichrome-
masson stain. Immunohistochemistry was performed as
described above by incubation with monoclonal mouse
antibodies for ASMA, vimentin, elastin and collagen I and III.
2.5.2. SDS-PAGE
Following lyphilization, samples of UCA, UCV and VC
were homogenized and treated with a collagenase digestion
procedure as described by Hayashi et al. [15]. Denaturated
samples, standards of collagen I and III (Calbiochem, La
Jolla, CA) and a high range molecular weight marker (Bio-
rad, Hercules, CA) were loaded onto a 10% sodium dodecyl
sulfate-polyacrylamide gel (SDS-PAGE). A 100 V potential
was applied across the gel for 80–90 min. The protein bands
were stained with Coomassie blue (Bio-rad, Hercules, CA).
2.5.3. Scanning and transmission electron microscopy
Additional samples of UCA, UCV, and UCC-seeded
polymer strips were fixed in 2% glutaraldehyde (Sigma, St
Louis, MI) and studied by transmission electron microscopy
(TEM) and scanning electron microscopy (SEM) at days 7,
14, 21 and 28.
2.5.4. Biomechanical testing
Longitudinal strips (20 £ 5 £ 1 mm3, n ¼ 5 of each
group) of UCA, UCV, UCC, and VC-seeded polymer strips
were uniaxial stress tested with an Instronw tensile analyzer
(model 4411) equipped with a 100 N load cell and
pneumatic clamps (max. pressure 75 psig) (Instron Corp.,
Canton, MA). The cross head speed was 0.5 inch/min
corresponding to a linear strain rate of 1 min21. The
mechanical properties were analyzed for maximum stress
and strain at maximal load.
3. Results
3.1. Histology and immunophenotyping of umbilical cords
Hematoxylin–eosin and Trichrome-masson staining of
sections of umbilical cord demonstrated the typical
formation of umbilical cords with two arteries and one
vein surrounded by Wharton’s jelly. The cells showed a
fibroblast-like morphology and good homogenous depo-
sition of extracellular matrix, predominantly in Wharton’s
jelly (Fig. 1A and B).
Staining with monoclonal antibodies against ASMA and
vimetin showed strong positive signals in the media of
umbilical artery and vein, while the signals were detected at
a lower level in cells of Wharton’s jelly (Fig. 1C and D).
3.2. Flow cytometry
Results of the FACS analysis of umbilical cord derived
cells and saphenous vein derived cells are shown in Fig. 2
and reveale comparable values for cell granularity and size.
Analysis for the expression of ASMA and vimentin by
UCA, UCV and UCC shows also comparable levels to those
of VC. No positive signal was detected for the endothelial
cell marker CD 31 among the isolated cell populations.
3.3. Histology and immunophenotyping of isolated
umbilical cord cells
Hematoxylin–eosin and Trichrome-masson staining of
fixed UCA, UCV and UCC cells showed elongated cells
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with fibroblast-like morphology and the deposition of
extracellular matrix throughout the cell culture. Immuno-
histochemistry revealed the intracellular expression of
ASMA and vimentin, both characteristic intracellular
filaments of myofibroblast. Cultured UCC did not stain
positive for CD 31, an endothelial cell marker.
3.4. MTT assay
Umbilical cord cells showed excellent cell growth. No
differences in cell growth potential between cultivated UCA
and UCV were detected by MTT assay analysis and
compared to previously investigated UCC and VC (Fig. 3)
[15].
3.5. Histology and immunohistochemistry of seeded polymer
strips
Hematoxylin–eosin and Trichrome-masson staining of
UCA, UCV and UCC-seeded polymer strips showed good
tissue formation (Fig. 1E). During the cultivation period, a
progessive cellular ingrowth and extracellular matrix
deposition was observed in the polymer strips. Immunohis-
tochemistry showed positive staining for ASMA and
vimentin, while the extracelluar matrix analysis demon-
strated the deposition of elastin and collagen I and III by all
three cell groups (Fig. 1F and G).
Fig. 1. Hematoxylin–eosin staining of a umbilical cord vein (A) and
Trichrome-masson staining of a umbilical cord artery (B) shows cells with a
fibroblast morphology and deposition of extracellular matrix proteins,
predominantly in Wharton’s jelly. Staining with monoclonal antibodies
against ASMA (C) and vimentin (D) shows strong positive signals in
umbilical cord vessels. Hematoxylin–eosin staining of a UCA strip shows
good tissue formation and cellular ingrowth into the polymer strips (E).
Immunohistology demonstrates the formation of elastin in a umbilical cord
vein strip (G). TEM image shows the deposition of collagen fibrils in a
umbilical cord artery seeded strip (H).
Fig. 2. Flow cytometry demonstrated no significant difference in the cell
morphology for cell size and granularity of UCA and UCV compared to VC
population (A). No difference was detected for the expression level of
vimentin, ASMA or CD 31 between UCA, UCV, UCC and VC (B). The
corresponding MFIR values are shown in each graph.
Fig. 3. MTT assay.
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3.6. SDS-PAGE
Results of the SDS-PAGE analysis are shown in Fig. 4.
The banding pattern of UCA and UCV probes are
comparable to VC probes. Corresponding bands are studied
at the range of collagen chains a1ðIÞ;a1ðIÞ; b and g as
described by Weston et al. [16].
3.7. Transmission and scanning microscopy
TEM of UCA, UCV and UCC sections of seeded patches
showed secretionally active myofibroblasts with deposition
of collagen fibrils (Fig. 1H). SEM analysis demonstrated
good cell-polymer attachment with a subsequent progress-
ive tissue formation during the cultivation period of 28 days.
No difference could be observed between UCA, UCV or
UCC seeded strips. Cells of all three groups formed a
confluent surface on both sides and grew well into the
deeper parts of the polymer. However, a continuous
degradation of the polymer scaffold was studied by multiple
breakages and fragmentation of the polymer fibers (Fig. 5).
3.8. Biomechanical testing
The biomechanical testing revealed comparable results
for UCA, UCV, UCC, and VC-seeded constructs in regard
to maximal uniaxial tensile stress testing (UCA:
0.158 ^ 0.024 MPa), UCV: 0.190 ^ 0.088 MPa, UCC:
0.264 ^ 0.093 Mpa, VC: 0.373 ^ 0.054 Mpa and to
distensibility (UCA: 0.0.389 ^ 0.212 mm/mm, UCV:
0.523 ^ 0.055 mm/mm, UCC: 0.385 ^ 0.047 mm/mm,
VC: 0.43 ^ 0.056 mm/mm).
4. Discussion
The results of the present study demonstrate that human
umbilical cord cells represent an attractive autologous cell
source for tissue engineering of cardiovascular constructs,
especially for the repair of congenital defects. Umbilical
cords were easy to obtain in segments between 20 and
30 cm length, which allows for the generation of a sufficient
cell number in a relatively short period of time. In order to
obtain a similar result by using cells of saphenous vein
origin, segments of a similar length would have to be
harvested from pediatric patients or higher cell passages
would be required prior to cell seeding.
The human umbilical cord is composed of two arteries
and one vein surrounded by embryonic connective tissue—
Wharton’s jelly [17]. Cells of umbilical cord artery,
umbilical cord vein and Wharton’s jelly, exhibit myofibro-
blast-like characteristics by co-expressing ASMA and
vimentin. Following immunohistological analysis, Kobaya-
shi et al. also observed no qualitative differences concerning
cytoskeletal differentiation and extracellular matrix mol-
ecules of arterial and venous umbilical cord vessel walls,
and further analysis of segments isolated from the distal,
middle, and proximal part of the umbilical cord shows no
significant differences in the longitudinal axis of the
umbilical cords [18].
Following isolation from segments of umbilical cord
artery, umbilical cord vein and whole cord, cultivated cells
continued to express myofibroblast morphology with a cell
size and granularity which was comparable to vascular
cells of saphenous vein origin. Furthermore, no difference
was detected in the expression levels of the myofibroblast
typical microfilament ASMA, or the intermediate filament
Fig. 5. SEM analysis of UCA, UCV and UCC strips show a good cell-
polymer attachment of the cells with a subsequent progressive tissue
formation during the cultivation period of 28 days. A seeded strip is shown
after 14 days (A and B), 21 days (C and D) and after 28 days (E and F).
Fig. 4. SDS-PAGE shows corresponding banding pattern at the range of
collagen chains a1(I), a1(2), b and g of UCA, UCV, and VC probes after
Coomassie blue staining. (MW, high range molecular weight marker).
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vimentin by cultivated UCA, UCV and UCC compared to
VC. Following seeding, cells of all three groups demon-
strated a good attachment and good growth pattern on the
polymer strips. A continuous formation of a confluent,
smooth tissue surface, and the deposition of extracellular
matrix, consisting of collagen I, III and elastin, was studied.
Further similarity of the extracellular matrix formation of
umbilical cord cells and vascular cells was demonstrated by
SDS-PAGE protein separation which revealed a comparable
collagen chain formation between UCA, UCV, UCC and
VC probes.
The importance of using arterial versus venous myofi-
broblasts for tissue engineering is, as yet, unclear. Schnell
et al. compared polymer strips seeded with fibroblasts
isolated from human aortic and saphenous vein segments in
an in vitro study [19]. They concluded that the saphenous
vein seeded strips showed a higher tissue maturity, collagen
formation and mechanical stability, compared to aortic
constructs. However, the authors do not provide any
information of the original cell sources, such as number of
patients, patient age, and existing comorbidities, such as
artherosclerosis, which may have a tremendous impact on
myofibroblast morphology and extracellular matrix for-
mation. In contrast, by using arterial and venous cell lines,
several groups report the successful generation of heart
valves, pulmonary conduits, and patch material [14,20–24].
There was no difference in performance or tissue formation
between the in vivo tested constructs.
The results of the present study did not show any
particular differences among UCA, UCV and UCC
compared to VC, concerning cell characteristics and tissue
formation under static cultivation conditions. It appears that
in regard to practical clinical application, cell isolation
could be performed from whole term umbilical cords.
However, further experiments exposing UCA, UCV and
UCC seeded constructs to a dynamic environment are
required to confirm these findings.
Umbilical cord cells represent an attractive cell source
for tissue engineering of cardiovascular structures for the
repair of congenital defects by offering the advantages of
avoiding the invasive harvesting of intact vascular struc-
tures from pediatric patients and the availability of
approximately 20–30 cm vascular tissue sections, which
allows the isolation of a large amount of juvenile, fast
growing cells for the generation of a sufficient cell number
for scaffold seeding in a short period of time.
Additional advantages of using umbilical cords as a cell
source for cardiovascular tissue engineering present the
possibility to preserve the post-partal cords by standard cell
and tissue banking technology to obtain an autologous cell
pool for the patient’s lifetime, and the isolation of
endothelial cells from the cord vessels to create an
endothelial layer on the tissue engineered constructs,
which may be crucial for their long-term function. The
evaluation of these concepts will be areas of future studies.
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